Moderna (MRNA) Stock Soars 14% on Personalized Cancer Vaccine Success: Is It Time to Buy?
Quick Summary Moderna shares climbed more than 14% following positive Phase 3 trial results for intismeran autogene, its personalized mRNA cancer vaccine Clinical data demonstrated that intis






